Overview

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Status:
Completed
Trial end date:
2019-07-10
Target enrollment:
Participant gender:
Summary
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with Non-Alcoholic Steatohepatitis
Phase:
Phase 2
Details
Lead Sponsor:
Enanta Pharmaceuticals
Collaborators:
ICON Clinical Research
Triangle Biostatistics